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Background: In the Highly Active Antiretroviral Therapy (HAART) era, the prognosis of children perinatally infected
with HIV-1 has significantly improved, so the number of perinatally-infected females entering child-bearing age and
experiencing motherhood is increasing.
Methods: A description of the medical history and pregnancy outcomes of women with perinatal acquired HIV-1
infection enrolled in the Italian Register for HIV infection in Children.
Results: Twenty-three women had 29 pregnancies. They had started an antiretroviral therapy at a median of
7.7 years (interquartile range, IQR 2.3 - 11.4), and had experienced a median of 4 therapeutic regimens (IQR 2–6).
Twenty women (87%) had taken zidovudine (AZT) before pregnancy, in 14 cases as a starting monotherapy. In 21
pregnancies a protease inhibitor-based regimen was used. At delivery, the median of CD4+ T lymphocytes was
450/μL (IQR 275–522), and no viral load was detectable in 15 cases (reported in 21 pregnancies). Twenty-eight children
were delivered through caesarean section (median gestational age: 38 weeks, IQR 36–38, median birth weight: 2550
grams, IQR 2270 – 3000). Intravenous AZT was administered during delivery in 26 cases. All children received oral AZT
(median: 42 days, IQR 31 – 42), with no adverse events reported. No child acquired HIV-1 infection.
Conclusions: Despite a long history of maternal infection, multiple antiretroviral regimens and, perhaps, the development
of drug-resistant viruses, the risk of mother-to-child transmission does not seem to have increased among the
second-generation of HIV-1 exposed infants.
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The introduction of Highly Active Antiretroviral Ther-
apy (HAART) has significantly improved the quality of
life and prognosis of children with perinatally acquired
HIV-1 infection in resource-rich countries [1,2]. As a re-
sult, an increasing number of these children are entering
adolescence and young adulthood, with a consequent
proportion of females becoming sexually active and
pregnant. These mothers presented with a long history
of HIV-1 infection and sometimes AIDS complications.
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unless otherwise stated.and to their, primarily metabolic, chronic side effects.
They experienced multiple ART regimens, which were
often sub-therapeutic until the advent of HAART, with a
consequent risk of acquiring drug-resistant viruses.
Therefore, it has since become crucial to define the
pregnancy outcome and effectiveness of ART therapy in
preventing mother-to-child HIV-1 transmission (MTCT)
in this 2nd generation of HIV-1 exposed infants. Reports
from Europe [3,4], Puerto Rico [5], India [6], USA [7-10],
and Brazil [11] describe favourable maternal and neonatal
outcomes, with a MTCT rate varying from 0 to 7.7%, de-
tected in cases of poor adherence to therapy [10].
Here, we describe the clinical aspects of pregnancy in
women with perinatally acquired HIV-1 infection enrolledtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Methods
The Italian Register for HIV infection in children (ITLR) is
a nationwide, multicentre, prospective study set up by the
Italian Association of Paediatrics in 1985. At the moment of
patient’s enrolment, written informed consent is obtained
from the patient’s guardians; data are treated anonymously
as each patient is identified by an alphanumerical code. The
study was approved by the review boards and ethics com-
mittees of each participating institution, as described in de-
tail elsewhere [1,12]. A retrospective analysis of perinatally
HIV-1 infected females, enrolled in the ITLR from its insti-
tution and who had a child, was carried out. Information
included: the women’s demographic and clinical character-
istics, such as their mothers’ risk factors for HIV-1 infection,
perinatal ART use, HIV-1 related diseases and comorbidi-
ties; the number and types of ART regimens both before
and during pregnancy; age at delivery, number of CD4+ T-
lymphocytes and viral load at delivery, the mode of delivery;
infants’ characteristics (gestational age, sex, birth weight,
congenital malformations, any other acute or chronic dis-
eases, adverse events for MTCT prophylaxis, HIV-1 infec-
tion status). SPSS (version 20.0) software for Windows was
used for data management.
Results
Between 2001 and 2012, 29 children were born to 23
women with perinatal HIV-1 infection. One woman had 3
pregnancies and four women had 2 pregnancies each. See
Tables 1, 2 and 3 for data concerning mother-child pairs.
The median maternal age at first delivery was 22 years
(interquartile range (IQR) 20.1-24.3); the oldest mother
was born in 1982, the youngest in 1991. No infected
mother was perinatally exposed to antiretroviral drugs, as
ART prophylaxis was not used at that time. The grand-
mothers’ risk factors for HIV-1 infection were known for
17 women: 11 had had high risk sexual intercourse and 6
had been IV drug users. All but one woman had ART
therapy during childhood or adolescence. The median age
at the start of ART therapy was 7.7 years (IQR 2.3-11.4).
The median number of regimens for each woman was 4
(IQR 2–6). Twenty (87%) women were given zidovudine
(AZT), in 14 cases as a starting monotherapy for a median
period of 4.4 years (IQR 2.0-5.2); 12/14 patients were later
shifted to a dual therapy containing AZT (median period
2.4 years, IQR 1.0-3.4). All but 2 women received HAART
before pregnancy, with a combination of 3 or more drugs,
containing at least one protease-inhibitor (PI) in 16 cases.
The median time of the mothers’ exposure to ART drugs
before their first pregnancy was 11.6 years (IQR 9.5-17.5).
Four women developed an AIDS defining condition (at a
median age of 9.0 years, IQR 1.8-12.7); 10 women wereclassified, according to the CDC paediatric classification,
in clinical category B, 8 in category A, 1 in category N. As
far as the immunological status is concerned, 5 were in
category 1, 8 in category 2, and 10 in category 3.
Ten mothers did not have any ART therapy at the
time of conception; of the ten, 2 continued without ther-
apy throughout their pregnancy, 4 started ART therapy
in the first trimester and 4 after the 12th week of gesta-
tion, including one woman who started a rescue therapy
including the integrase inhibitor raltegravir at the 38th
week of gestation. In the other pregnancies, the women
were already undergoing ART treatment at conception,
and 3 of them discontinued therapy in the first trimester
(see Table 2). In one case, efavirenz (EFV) was continued
during the first 5 weeks of gestation, with a switch to a
lopinavir/ritonavir containing combination after the 12th
week. A PI-based regimen was used in a total of 21 preg-
nancies. No complications related to pregnancy were no-
ticed. There was a median of 450/μL (IQR 275–522)
CD4+ T lymphocytes at the last check before delivery
(reported in 23 of the 29 pregnancies); all women with a
previous AIDS-defining condition had > 200 CD4+/μL.
The viral load at delivery (reported in 21 pregnancies)
was undetectable in 15 cases. Intravenous AZT was ad-
ministered during 26 (89.6%) deliveries. Twenty-eight
children were born through caesarean section, which
was elective in 26 cases. No neonatal complications for
children at birth were reported; 17 (58.6%) were females;
their median gestational age was 38 weeks (IQR 36–38)
and the median birth weight was 2550 grams (IQR
2270–3000). Eight were preterm (<37 weeks of gesta-
tion), and 4 were small for the gestational age (SGA)
(Table 3) [13]. No infant was breastfed. Twenty-six in-
fants received oral AZT as MTCT prophylaxis; 2 broth-
ers received a combined regimen (AZT + 3TC +NVP
single dose): the first child because of lack of maternal
ART therapy during pregnancy, the second one because
of severe maternal immunosuppression (CD4+ T-
lymphocytes at labour: 95 cell/ μL). Neonatal ART
prophylaxis was administered for a median period of
42 days (IQR 31–42) with no major adverse events.
No child acquired HIV-1 infection. One patient was
HCV infected and one presented cryptorchidism. The
median age at the last check was 3 years (IQR 1.3-4.3),
with nine children followed over 4 years of age.
Discussion
There are few studies exploring the pregnancy outcome
in HIV-1 perinatally-infected women. Despite the lim-
ited number of pregnancies enrolled and limited amount
of available data, ours is one of the largest cohorts with
detailed information on the entire maternal history.
The results are reassuring, since none of the 29 ex-
posed infants acquired the infection. Indeed, of the 134
Table 1 Characteristics of HIV-1 vertically infected women
N. Birth
order
Risk factors for HIV
infection in grandmothers
Year of
birth
Age (years) at
start of ART
therapy
AZT
monotherapy
No of
regimens
experienced
Years of ART
therapy (before the
first pregnancy)
Clinical and
immunological
category at last
observation
Age (years)
at AIDS onset
Age (years)
at delivery
Case 1 1st Drug abuse 1982 14.6 No 4 13.2 A 1 28.4
Case 2 1st Sexual intercourse with drug abuser, Drug abuse 1982 10.6 Yes 5 7.7 B 3 24.6
2nd 26.9
Case 3 1st Risk sexual intercourse 1983 7.7 Yes 6 17.5 B 3 26.1
Case 4 1st Drug abuse 1983 11.4 Yes 7 7 B 3 23.9
Case 5 1st Unknown 1983 21.7 No 1 0 B 3 22
2nd 23.7
3th 24.7
Case 6 1st Drug abuse 1984 6.6 Yes 6 9.7 B 2 17
2nd 18.3
Case 7 1st Sexual intercourse with drug abuser 1985 3.1 No 2 20.5 N 2 24.3
Case 8 1st Drug abuse 1985 3 Yes 15 17.7 C 3 11.5 22.4
Case 9 1st Sexual intercourse with drug abuser, Drug
abuse
1986 12.2 No 2 9.5 C 2 13.1 22.2
Case 10 1st Sexual intercourse with drug abuser 1986 6.6 Yes 6 14.8 C 3 6.6 22.1
Case 11 1st Unknown 1986 10.2 No 6 11.1 A 3 22
Case 12 1st Sexual intercourse with drug abuser 1986 10 Yes 3 6.3 A 2 21.1
2nd 22.2
Case 13 1st Unknown 1986 13.3 No 1 11 A 1 25
Case 14 1st Sexual intercourse with drug abuser 1987 2.3 Yes 3 21.6 B 2 24.5
Case 15 1st Unknown 1988 14.4 No 2 10.3 B 1 22.6
Case 16 1st Unknown 1988 1.9 Yes 2 6.2 A 2 19.2
Case 17 1st Sexual intercourse with drug abuser 1989 1.8 Yes 5 18 A 1 20.3
Case 18 1st Sexual intercourse with drug abuser, Drug abuse 1990 1.7 Yes 5 14.4 B 2 20.1
Case 19 1st Drug abuse 1990 5.4 Yes 8 13.9 B 3 20
Case 20 1st Unknown 1990 8.6 No 4 11.6 A 3 20.8
2nd 21.7
Case 21 1st Sexual intercourse with drug abuser 1991 1.2 Yes 3 17.3 B 1 19.3
Case 22 1st Drug abuse 1991 0.6 Yes 7 19.2 C 3 0.2 20.4
Case 23 1st Sexual intercourse with drug abuser, Drug abuse 1991 8.2 No 2 9.9 A 2 20
Legend. ART = antiretroviral; AZT = zidovudine.
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Table 2 Pregnancy features
N. Birth
order
ART therapy
at conception
ART therapy interruption
at first trimester
ART regimen during pregnancy Gestational
week at start
Gestational
week at end
CD4+ at delivery VL at delivery AZT intrapartum Type of
delivery
Case 1 1st No No AZT + 3TC + ATV/rtv 5 37 525 Undetectable Yes EC
Case 2 1st Yes Yes (from 5th to 12th week) DDI + 3TC + NVP 1 4 480 157 Yes EC
AZT + 3TC + NVP 13 38
2nd Yes No FTC + TDF + FPV/rtv 1 38 520 Undetectable Yes EC
Case 3 1st Yes No FTC + TDF + ATV/rtv 1 38 125 Undetectable Yes EC
Case 4 1st No No No Unknown Unknown Yes EC
Case 5 1st No No AZT + 3TC + LPV/rtv 23 34 307 Unknown Yes EC
2nd Yes No AZT + 3TC + LPV/rtv 1 37 480 15332 Yes EC
3th Yes No AZT + 3TC + LPV/rtv 1 Unknown Unknown Unknown Yes EC
Case 6 1st No No AZT + 3TC + NVP 6 36 Unknown Unknown No EC
2nd No No AZT + 3TC + NVP 6 40 Unknown Unknown No EC
Case 7 1st Yes No ABC + 3TC + ATV 1 34 323 Undetectable Yes EC
ABC + 3TC + ATV/rtv 35 38
Case 8 1st Yes No FTC + TDF + DRV/rtv 1 38 450 Undetectable Yes EC
Case 9 1st Yes No ABC + DDI + LPV/rtv 1 16 312 7653 Yes EC
AZT + 3TC + LPV/rtv 17 36
Case 10 1st Yes Yes (from 6th to 12th week) FTC + TDF + EFV 1 5 240 Undetectable Yes EC
AZT + 3TC + LPV/rtv 13 38
Case 11 1st Unknown No ABC + TDF + LPV/rtv Unknown 39 Unknown Undetectable Yes EC
Case 12 1st No No No Unknown Unknown Yes UC
2nd Yes No AZT + 3TC + LPV/rtv 1 38 95 Unknown Yes EC
Case 13 1st Yes No FTC + NVP 1 39 673 Undetectable Yes EC
Case 14 1st Yes No AZT + 3TC + ABC 1 35 564 Undetectable Yes EC
Case 15 1st Yes No FTC + TDF + DRV/rtv 1 37 501 Undetectable Yes EC
Case 16 1st No No FTC + TDF + ATV/rtv 16 36 522 Undetectable Yes EC
Case 17 1st No No FTC + TDF + ATV 13 37 770 Undetectable Yes EC
Case 18 1st Yes No 3TC 1 28 440 13099 Yes LC
FTC + TDF + DRV/rtv 29 36
Case 19 1st No No FTC + TDF + ATV/rtv 6 38 501 Undetectable Yes EC
Case 20 1st No No FTC + TDF + DRV/rtv + RAL 38 40 200 Undetectable Yes EC
2nd Unknown Unknown Unknown 99 Unknown Unknown Unknown
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Table 2 Pregnancy features (Continued)
Case 21 1st Yes No FTC + TDF + ATV/rtv 1 38 776 615 Yes EC
Case 22 1st Yes No AZT + DDI + LPV/rtv 1 35 435 Undetectable Yes EC
Case 23 1st Yes Yes (from 3rd to 9th week) FTC + TDF + LPV/rtv 1 3 275 20000 Yes EC
FTC + TDF + LPV/rtv 10 38
Legend. VL: viral load (copies/ml); AZT: zidovudine; 3TC: lamivudine; ABC: abacavir; FTC: emtricitabine; TDF: tenofovir; DDI: didanosine; NVP: nevirapine; LPV: lopinavir; ATV: atazanavir; FPV: fosamprenavir;
DRV: darunavir; rtv: ritonavir booster; RAL: raltegravir; EC = elective caesarean section; UC = unspecified caesarean section; LC = caesarean section after labour.
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Table 3 HIV-1 exposed children features
N. Birth
order
Year of
birth
Gender Gestational
age (weeks)
Weight at
birth (grams)
ART
prophylaxis
Duration of postnatal
ART prophylaxis (days)
HIV-1
status
Other pathological
conditions
Case 1 1st 2010 M 37 2590 AZT 42 SR
Case 2 1st 2007 F 38 2550 AZT 45 SR
2nd 2009 M 38 3240 AZT 19 SR
Case 3 1st 2009 F 38 3100 AZT 28 SR
Case 4 1st 2007 F 38 2920 AZT 36 SR
Case 5 1st 2005 F 34 1975 AZT 42 SR
2nd 2007 F 37 1960 SGA AZT 42 SR HCV infection
3th 2008 F Unknown Unknown AZT 28 SR
Case 6 1st 2001 F 36 1880 SGA AZT 44 SR
2nd 2002 F 40 3080 AZT 42 SR
Case 7 1st 2009 M 38 2530 AZT 42 SR
Case 8 1st 2008 F 38 2450 AZT 43 SR
Case 9 1st 2008 F 36 2520 AZT 42 SR
Case 10 1st 2008 M 38 3250 AZT 31 SR
Case 11 1st 2008 F 39 2770 AZT 41 SR
Case 12 1st 2007 M 35 2270 AZT + 3TC + NVP 31 SR
2nd 2008 M 38 3000 AZT + 3TC + NVP 42 SR
Case 13 1st 2011 M 39 3100 AZT 41 SR
Case 14 1st 2011 F 35 1190 SGA AZT 18 SR
Case 15 1st 2011 M 37 3190 AZT 42 SR
Case 16 1st 2008 F 36 2760 AZT 42 SR
Case 17 1st 2009 M 37 2520 AZT 29 SR Cryptorchidism
Case 18 1st 2010 M 36 2180 AZT 42 SR
Case 19 1st 2010 F 38 2500 AZT 14 SR
Case 20 1st 2011 F 40 2380 SGA AZT 45 SR
2nd 2012 F Unknown Unknown Unknown Unknown SR
Case 21 1st 2010 F 38 2750 AZT 42 SR
Case 22 1st 2012 M 35 2160 AZT 42 SR
Case 23 1st 2011 M 38 2690 AZT 33 SR
Legend. M =male; F = female; AZT = zidovudine; 3TC = lamivudine; NVP = nevirapine; SR = seroreverter; SGA= small for gestational age.
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scribed in this and other studies [3-11], only 2 acquired
the infection, for a total MTCT rate of 1.5%, comparable
to that observed in the first-generation of exposed in-
fants with the adoption of the same preventive measures,
such as ART therapy during pregnancy, elective caesar-
ean section, ART prophylaxis in the child, and bottle-
feeding [12,14,15].
Among 601 women with perinatally acquired HIV-1
infection enrolled in the ITLR, 383 are alive and over
16 years old at the last check. Thus, the 23 described in
this case-series represent 6% of those with a similar
child-bearing age. It is worth noting that 5 had more
than one child. In spite of the prolonged history of HIV-
1 infection and of targeted therapies, the good quality oflife and a longer life expectancy presumably allowed
these women to live motherhood with fewer distressing
concerns. The low probability of HIV-1 transmission to
the offspring is an additional important factor support-
ing such women having children. We have no documen-
tation about the possible birth control methods adopted
by these women, or whether these pregnancies were
planned. However, the median age of our parturients
was rather lower than the 32.3 years observed in the
general Italian population [16]. This low median age at
delivery is consistent with other reports [3,5,6,10], and,
perhaps, mirrors the fear that the chronic disease could
deprive them of the special female role of motherhood.
This growing desire of motherhood among seropositive
women clearly emerges from our Register, where the
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350–400 per year, with an increasing multiparity rate,
reaching 25% in recent years (data not shown).
In this scenario, the management of HIV-1 perinatally-
infected pregnant women and their children will be an
important challenge for clinicians in the near future. A
crucial aspect will be the choice of the best ART regi-
men to prevent MTCT. None of our mothers was peri-
natally exposed to ART drugs, as they were born before
the ACTG 076 protocol [17,18]. However, the majority
received ART therapy during childhood and experi-
enced several sub-therapeutic regimens. Although re-
sistance data were not available, these conditions are
well known to favour the development of drug resistant
viruses, with a consequent possible higher risk of
MTCT, a phenomenon that fortunately does not
emerge from the available data. As far as AZT is con-
cerned, it is worth noting that over half of our mothers
started AZT as a monotherapy during childhood, then
shifted to a dual therapy including AZT, continuing
with such combinations for several years. Six of these
14 women continued to receive AZT also during preg-
nancy, as did all their children as a prophylaxis, appar-
ently with success, since the majority of the mothers
had undetectable viral loads at delivery and no child ac-
quired the infection. This casts doubts on the suggested
exclusion of AZT during pregnancy if there had been a
prolonged monotherapy during childhood [10]. Indeed,
in a recent case series the role of intrapartum intraven-
ous AZT for the prevention of MTCT in women with
virological failure has been stressed [19]. AZT may be
effective in the prevention of MTCT through other
mechanisms besides its direct antiviral effect [18,20].
The possible impact of a prolonged ART therapy on
maternal and child health is a further important as-
pect. Even in this context, our results are reassuring.
No congenital abnormalities were noticed, including
the child exposed to EFV in the first 5 weeks of gesta-
tion [21,22]. Since maternal and neonatal complica-
tions due to ART drugs do not seem to be higher in
perinatally-infected women, indications should not dif-
fer from those commonly recommended in seroposi-
tive mothers, for instance HAART should start as soon
as possible [15], while stopping ART during pregnancy
should be discouraged [12]. In fact, fearing a possible
teratogenicity, 3 women discontinued ART treatment
during the first trimester of pregnancy and their viral
load was detectable at delivery. On the other hand, the
experience of several therapeutic regimens during
childhood and adolescence will presumably lead to the
use of new antiretroviral drugs during pregnancy, such
as integrase inhibitors, the impact of which on preg-
nant women and their foetuses still needs to be
elucidated.Conclusions
The outcome of second-generation HIV-1 exposed in-
fants seems favourable. In spite of a long course of ma-
ternal infection, multiple ART regimens, and a possible
development of drug-resistant viral strains, MTCT con-
tinues to be efficiently controlled by the commonly
adopted preventive strategies, even though an adequate
surveillance of pregnancy among this unique population
is highly recommended.
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